7 JCI-accredited hospitals · 45+ hospitals & clinics · 90+ countries served · 24/7 multilingual support
Cancer Care

Reading a Hormone Therapy Plan for Breast or Prostate Cancer: What to Ask Your Oncologist

25 min read
Reading a Hormone Therapy Plan for Breast or Prostate Cancer: What to Ask Your Oncologist

Key Takeaways

  • Hormone therapy for breast cancer is used only when the tumor tests positive for estrogen or progesterone receptors, so asking for the actual receptor result is the first question on any plan.
  • Tamoxifen blocks the estrogen receptor and works before or after menopause, while aromatase inhibitors lower estrogen production and are used alone only after the ovaries have stopped functioning.
  • Adjuvant endocrine therapy for early breast cancer typically runs 5 to 10 years, and androgen deprivation given with radiotherapy for localized prostate cancer ranges from several months to about three years depending on risk.
  • GnRH agonists can cause a brief testosterone flare in the first weeks after the first injection, which is why an antiandrogen is often prescribed to cover that window.
  • Bone density, weight, blood pressure, glucose and lipids belong on the monitoring list for men on long-term androgen deprivation therapy, because the treatment affects bone and cardiovascular health as well as the prostate.
  • Feeling well during hormone therapy is the expected state and not a sign that treatment can stop; side effects reflect falling hormone levels, not whether the cancer is responding.
Quick Answer

When you review a hormone therapy plan for breast or prostate cancer, the most useful questions cover five areas: why your tumor is expected to respond (receptor or androgen sensitivity), which drug class is proposed and why, how long treatment is planned, which side effects will be monitored and how, and what happens if the plan needs to change. Written answers from your oncology team make the plan easier to follow.

The envelope says “treatment summary,” and inside is a single page that will shape the next five years. One line reads “endocrine therapy, adjuvant, 5 years, review bone density.” Another, in a different clinic across town, reads “ADT, 18 months, with radiotherapy, PSA every 3 months.” Both patients nod in the consulting room. Both go home and search the terms on their phones at midnight.

That gap between nodding and understanding is where this article lives. The questions to ask about hormone therapy are not complicated, but they are specific, and they are easier to raise when you know what each line on the plan is trying to accomplish and what the evidence behind it actually says.

Breast and prostate cancers sit on opposite sides of the body and affect different people, yet the logic of hormone therapy for both is strikingly similar: starve a tumor of the hormonal signal it has learned to depend on. Once that logic is clear, the plan becomes a document you can interrogate rather than one you simply accept.

Questions to ask about hormone therapy begin with your pathology report

Before any drug name appears, the plan rests on a laboratory finding. For breast cancer, that finding is receptor status. A receptor is a protein on or inside a cell that acts like a docking station for a hormone; when estrogen or progesterone docks, the cell is told to grow. Pathologists stain a sample of the tumor and report whether estrogen receptors (ER) and progesterone receptors (PR) are present. According to the National Cancer Institute, most breast cancers are hormone receptor positive, and only those tumors are expected to respond to endocrine therapy, which is simply the clinical name for hormone therapy.

For prostate cancer, the equivalent finding is less about staining and more about biology: nearly all prostate cancers rely on androgens, the group of male sex hormones that includes testosterone, so sensitivity is assumed at the start and then confirmed by watching how the cancer behaves once androgen levels fall.

Your first question, therefore, is deceptively simple: “What in my report tells you this cancer is hormone sensitive, and how strongly?” For breast cancer, ask for the actual percentage of cells that stained positive and whether the result was weak or strong, because a weakly positive tumor sometimes prompts a different conversation than a strongly positive one. For prostate cancer, ask what the baseline prostate-specific antigen (PSA) level is. PSA is a protein made by prostate cells and measured in blood, and the plan will use it as the main gauge of response.

A second question follows naturally: “Were any other markers tested, and did they change the recommendation?” In breast cancer that may include HER2 status, a growth-signal protein, and in some cases a gene expression test on the tumor. The answers do not change the hormone therapy itself, but they explain why it may be given alone or alongside other treatments.

How hormone therapy actually works in breast cancer

Picture estrogen as a key and the tumor cell’s receptor as a lock. Endocrine therapy for breast cancer works by either jamming the lock or taking away the keys, and the two main drug classes correspond to those two strategies.

Female doctor consulting with older male patient: How hormone therapy actually works in breast cancer

Selective estrogen receptor modulators, a class that includes the generic drug tamoxifen, sit in the receptor and block estrogen from docking. The medicine behaves like a key that fits but will not turn. Because it blocks the receptor rather than the hormone, it works whether or not the ovaries are still producing estrogen, which is why the Mayo Clinic describes it as an option both before and after menopause.

Aromatase inhibitors take the other route. After menopause the ovaries largely stop making estrogen, but an enzyme called aromatase, found in fat, muscle and other tissues, keeps converting small amounts of androgens into estrogen. Aromatase inhibitors switch that enzyme off, so circulating estrogen falls to very low levels. The National Cancer Institute notes that, on their own, these drugs are intended for people whose ovaries are no longer active, because functioning ovaries would simply override the blockade.

A third approach, ovarian suppression, removes or quiets the main estrogen source in premenopausal patients. This can be done with injections of a gonadotropin-releasing hormone (GnRH) agonist, a drug that shuts down the brain’s signal to the ovaries, or by surgical removal of the ovaries. Ovarian suppression is sometimes combined with an aromatase inhibitor or with tamoxifen.

None of these treatments kills cancer cells outright in the way chemotherapy does. They remove the growth signal, slowing or halting the division of any cells that remain after surgery, which is why the plan is measured in years rather than weeks. Asking “Which of these mechanisms is my plan using, and why that one for me?” is the quickest way to make the drug name meaningful.

How hormone therapy actually works in prostate cancer

Prostate cancer cells run on testosterone the way a furnace runs on fuel. Androgen deprivation therapy (ADT), the umbrella term for hormone treatment in prostate cancer, cuts the fuel supply, and clinicians have several ways to do it.

Most testosterone is made in the testicles on instruction from the pituitary gland at the base of the brain. GnRH agonists, given as injections or implants under the skin, first overstimulate and then exhaust that instruction, so testosterone drops to very low levels. The National Cancer Institute describes an early “flare,” a brief rise in testosterone during the first weeks after the first injection, which is why an antiandrogen tablet is often prescribed around that time. GnRH antagonists block the same signal directly and do not cause a flare. Surgical removal of the testicles, called orchiectomy, achieves the same hormonal effect permanently and is still listed by the NHS as an option.

Androgen receptor blockers work downstream. Even with testicular production shut down, the adrenal glands and the tumor itself can make small amounts of androgen. Antiandrogens occupy the receptor so that whatever hormone remains cannot deliver its message. Newer androgen receptor pathway inhibitors, used in specific situations such as cancer that has spread, either block the receptor more completely or inhibit androgen production elsewhere in the body.

The response is tracked with PSA. When the fuel supply is cut, a hormone-sensitive tumor usually makes less PSA, and the plan will specify how often blood is drawn. Over time some cancers adapt to low testosterone, a state clinicians call castration-resistant, and the plan may then change. A sensible question at the outset is: “Which part of the androgen pathway does my treatment target, and what would tell you it is working?” The answer anchors every later conversation about PSA numbers.

Decoding the words on the plan: adjuvant, neoadjuvant, intermittent and more

Treatment summaries are written in shorthand, and a handful of terms do most of the work. Learning them turns the page from a code into a narrative.

Doctor consulting with patient about medical documents: Decoding the words on the plan: adjuvant, neoadjuvant, intermittent

Adjuvant means given after the main treatment, usually surgery or radiotherapy, to lower the chance of the cancer returning. Neoadjuvant means given before, often to shrink a tumor so that surgery is simpler. Primary hormone therapy means it is the main treatment rather than a supporting one, a pattern more common in prostate cancer or in people who are not candidates for surgery. The NHS breast cancer treatment pages use exactly this framing.

Continuous versus intermittent applies mainly to ADT. In an intermittent schedule, treatment is paused once PSA falls to a set level and restarted if it climbs again. The National Cancer Institute reports that intermittent approaches have been studied as a way to reduce side effects, with the oncologist judging whether they are appropriate for a particular situation.

Line of therapy refers to sequence: first-line is the initial plan, second-line is what follows if the first stops working. Extended endocrine therapy describes continuing beyond the standard period in breast cancer.

Monitoring entries tell you what will be measured. For breast cancer plans that may include bone density scans, called DEXA scans, and routine gynecologic review. For prostate plans it usually includes PSA, testosterone, and sometimes blood sugar, cholesterol and bone density.

Questions worth writing in the margin include: “Is this adjuvant or primary?”, “Is the schedule continuous or intermittent, and what would trigger a change?”, and “Which of these monitoring tests happen automatically and which do I need to request?” Each term on the page should map to a reason you can repeat back in your own words.

Who is usually offered hormone therapy, and who is usually asked to wait

Eligibility is a conversation about biology and timing, and it differs between the two cancers.

In breast cancer, the Mayo Clinic summarizes the principle plainly: endocrine therapy is offered only when the tumor is hormone receptor positive. A receptor-negative tumor has no lock for the drug to jam, so the treatment is not used. Within receptor-positive disease, the therapy is a standard component after surgery for early-stage cancer, may be used before surgery, and is a mainstay when cancer has spread. Menopausal status steers the choice of agent rather than whether treatment is offered.

Some patients are asked to wait or to hold. Endocrine therapy is often started after chemotherapy finishes rather than alongside it, and in some plans it begins after radiotherapy. Someone with a history of blood clots or certain uterine conditions may have one class steered away from in favor of another. Pregnancy, or a wish to become pregnant, requires a dedicated discussion, because these drugs are not used during pregnancy.

In prostate cancer, the NHS describes hormone therapy as commonly combined with radiotherapy for cancer that has not spread, or used on its own when the cancer has spread or when other treatments are not suitable. People with very low-risk, slow-growing disease are often not offered it at all; active surveillance, meaning scheduled PSA tests and scans without treatment, may be the recommended path. Men with significant heart disease or osteoporosis are not excluded, but the plan usually names those risks and adds monitoring.

The questions here are about fit: “What about my situation makes this the right time to start?”, “Is there anyone with my profile who would reasonably be advised to wait or watch instead?”, and “Which of my other health conditions did you weigh when choosing this class?” A good plan has already answered these; your job is to make the reasoning visible.

Tamoxifen or aromatase inhibitor: what the choice usually depends on

Patients with breast cancer often arrive at this fork and assume one option must be “stronger.” The reality, as the National Cancer Institute’s fact sheet lays out, is that the decision turns mostly on menopausal status and on which side-effect profile suits the individual.

Tamoxifen can be used before or after menopause. Its best-known risks, both uncommon but real, are blood clots in the legs or lungs and a small increase in the risk of cancer of the uterine lining in postmenopausal women. Hot flashes and vaginal discharge are frequent. Because it has a mild estrogen-like effect on bone, it does not thin bone in postmenopausal patients.

Aromatase inhibitors are used in postmenopausal patients, or in premenopausal patients only when combined with ovarian suppression. They do not carry the uterine or clotting concerns of tamoxifen, but they commonly cause joint and muscle aches and they accelerate bone loss, which is why bone density scans appear on the plan. Vaginal dryness and hot flashes are also common.

Many plans use both over time: a period of one followed by a switch to the other. Switching is also a recognized response to side effects that will not settle, which is worth knowing before you assume you must either tolerate symptoms or stop altogether.

Useful questions include: “Which of my characteristics pointed you toward this class?”, “If I struggle with it, is switching an option, and after how long would you consider that?”, “How will my bones be checked, and how often?”, and “What symptoms should make me think of a clot?” Ask also whether any over-the-counter products or supplements interact with your specific medicine, since a few common ones do, and have the answer recorded on the plan rather than remembered from the room.

Androgen deprivation therapy side effects and what should be monitored

Lowering testosterone changes more than the prostate, and the best plans say so in writing. The National Cancer Institute and the NHS list a consistent set of effects, which fall into four groups.

The first group arrives early. Hot flashes, reduced sex drive and difficulty with erections are among the most commonly reported. Fatigue often builds over the first months. Some men notice breast tenderness or enlarged male breast tissue (gynecomastia), particularly with antiandrogen tablets.

The second group is metabolic. Muscle mass tends to fall and fat tends to rise, especially around the waist. Blood sugar and cholesterol can shift, and the Mayo Clinic notes an association between long-term ADT and higher cardiovascular risk. This is why blood pressure, weight, glucose and lipids belong on the monitoring list, and why the plan may involve your primary care clinician as well as your oncologist.

The third group is skeletal. Testosterone helps maintain bone; without it, bone density declines and fracture risk rises over years. A baseline bone density scan and periodic repeats are standard considerations, alongside advice on weight-bearing exercise and dietary calcium and vitamin D.

The fourth group is cognitive and emotional. Mood changes, lower motivation and difficulty concentrating are reported by some men and are easy to dismiss as “just stress.” They deserve to be named at every review.

Questions to raise: “Which of these will you actively check, and at what interval?”, “Who manages my heart and bone health during this treatment?”, “Is intermittent therapy something you would consider for me, and what evidence applies to my situation?”, and “If erections or desire matter to me, what support exists and when should I ask for it?” None of these effects means the treatment is wrong; they mean the plan should account for the whole person.

How long does hormone therapy last? Typical ranges and what changes them

Duration is the question patients ask most, and it is the one most often answered with a shrug. The evidence supports clearer language than that.

For early breast cancer, the National Cancer Institute reports that adjuvant endocrine therapy is typically taken for 5 to 10 years, and the Mayo Clinic describes a minimum of about five years in most plans. Whether a given person is advised to continue to the longer end depends on features such as lymph node involvement, tumor size, how the first five years were tolerated and the person’s own priorities. Extending treatment trades a further reduction in recurrence risk against more years of side effects, and that trade should be explained in numbers specific to you, not in generalities. For breast cancer that has spread, hormone therapy continues for as long as it is controlling the disease and remains tolerable, with regular scans to judge both.

For prostate cancer that has not spread, ADT given with radiotherapy ranges from several months to around three years depending on how aggressive the cancer looks, a span consistent with NHS guidance and the National Cancer Institute’s descriptions. Short courses are used for intermediate-risk disease and longer ones for high-risk disease. When prostate cancer has spread, ADT is usually ongoing, sometimes with planned breaks under an intermittent schedule.

Three questions sharpen any timeline: “What is the planned end date, and what evidence set it?”, “What results or events would shorten or extend it?”, and “If I stop early for side effects, what do we know about the consequences?” Ask, too, about what happens at the end: for breast cancer, whether follow-up changes; for prostate cancer, how long testosterone typically takes to recover and whether it always does, which varies with age and treatment length.

Breast and prostate hormone therapies side by side

Seeing the two cancers in one frame highlights how much they share and where they part ways. The table summarizes the mainstream picture described by the National Cancer Institute, the NHS and the Mayo Clinic; it is a reading aid, not a menu.

Feature Breast cancer (hormone receptor positive) Prostate cancer
Hormone being targeted Estrogen, sometimes progesterone Androgens, mainly testosterone
Main drug classes Selective estrogen receptor modulators; aromatase inhibitors; ovarian suppression (GnRH agonist or surgery) GnRH agonists and antagonists; antiandrogens; androgen receptor pathway inhibitors; orchiectomy
How response is judged Absence of recurrence on follow-up; scans if disease has spread PSA blood level, testosterone level, scans when indicated
Typical duration (early disease) 5 to 10 years after surgery Several months to about 3 years alongside radiotherapy
Frequently reported effects Hot flashes, vaginal dryness, joint aches, mood changes Hot flashes, fatigue, reduced libido, erectile difficulty, muscle loss
Longer-term monitoring Bone density (aromatase inhibitors); uterine symptoms and clot awareness (tamoxifen) Bone density, weight, blood pressure, glucose, lipids
Role of timing Often starts after chemotherapy or radiotherapy May start before, during and after radiotherapy

Two patterns stand out. First, both treatments are long, and both ask the body to live without a hormone it has used since puberty, so the side effects are less like a drug reaction and more like an accelerated version of menopause or andropause. Second, monitoring is not an optional extra in either case; it is how the plan protects bones, heart and quality of life while the cancer is held in check.

Bring the table to your appointment if it helps, and ask your team to point to the row that applies to you and to cross out anything that does not. A plan annotated in the clinician’s own hand tends to be remembered.

What the first weeks on hormone therapy usually look like

Day one is quieter than most people expect. Unlike chemotherapy, there is no infusion chair and no immediate change in how you feel; a tablet is swallowed with breakfast, or an injection is given in the clinic and you drive home. The changes arrive over weeks, and knowing the usual sequence helps you distinguish expected adjustment from something that needs a call.

For breast cancer, hot flashes and night sweats are often the first visible effect, typically emerging within the first few weeks and fluctuating in intensity over the first months, as the Mayo Clinic’s overview describes. Joint stiffness with aromatase inhibitors tends to be most noticeable on waking and may take several weeks to appear. Many people describe a period of adjustment, after which symptoms settle into a pattern they can plan around. Keeping a brief symptom diary during this stretch gives your team concrete material at the first review.

For prostate cancer, the National Cancer Institute’s description of the testosterone flare matters here: after a first GnRH agonist injection, testosterone can rise briefly before it falls, and any antiandrogen tablet prescribed to cover that window should be taken exactly as the plan states. Testosterone usually reaches very low levels within a few weeks, which is when hot flashes and fatigue tend to begin. The first PSA check after starting is a milestone; ask in advance when it will be drawn and how the result will reach you.

Across both cancers, the practical items in the first weeks are administrative as much as medical: confirming how repeat prescriptions or injection appointments are organized, knowing which phone number to use for side effects, and booking the baseline tests the plan calls for, such as a bone density scan. People who sort these early tend to describe the first months as manageable rather than chaotic. Ask your team to write the first three appointments on the plan itself.

Hormone therapy side effects: describing them so they get addressed

Side effects are the main reason people stop hormone therapy early, and the National Cancer Institute’s fact sheets are candid that stopping early reduces the benefit. The practical answer is not grit; it is reporting symptoms in a way that lets clinicians act.

Describe frequency, timing and impact rather than labels. “Hot flashes” tells your team little; “eight to ten a day, worst at 3 a.m., waking me three nights a week” tells them a great deal, and it is the kind of detail that leads to a specific response, whether that is a non-hormonal medicine, a change in timing, or a referral. The same applies to joint pain (which joints, morning or evening, does movement help), to fatigue (does a short walk improve or worsen it), and to mood (low, flat, anxious, irritable, and since when).

Sexual and genitourinary effects are underreported in both cancers and are among the most treatable. Vaginal dryness, pain with intercourse, loss of desire and erectile difficulty each have recognized management options, some of them non-drug. Raise them in the same breath as hot flashes rather than saving them for “if it gets worse.”

Bone and heart health belong in this conversation as well. Weight-bearing exercise, resistance training, adequate calcium and vitamin D, and not smoking are the evidence-based foundations named by the Mayo Clinic and NHS for people on either treatment, and they also blunt the metabolic shifts of ADT. If a bone density scan or lipid check on the plan has not happened, say so.

Questions that move things forward: “What is the usual first step for this symptom?”, “At what point would you change the medicine rather than treat the side effect?”, “Is there a specialist nurse, pharmacist or menopause or sexual health service I can be referred to?”, and “Which of my symptoms, if any, suggests something other than the treatment?” A side effect you can describe is a side effect that can be managed.

What people often get wrong about hormone therapy

Myths cluster around hormone therapy because it is quiet, long and poorly explained. Correcting a few of them changes how people approach the plan.

“It is a mild treatment, so it must matter less.” The opposite is closer to the truth. For hormone receptor positive breast cancer, the National Cancer Institute describes endocrine therapy as one of the main reasons recurrence rates have fallen, and for prostate cancer ADT is the backbone of treatment for advanced disease. Its lack of drama is a feature of its mechanism, not a measure of its importance.

“If I feel fine, I can stop.” The therapy works on cells you cannot feel. Feeling well is the expected state, not a sign the job is done. Stopping is a decision for the treating team, informed by evidence on duration, not by the absence of symptoms.

“Hormone therapy means I am being given hormones.” Both treatments remove or block hormones. The confusion with menopausal hormone replacement is common and worth clearing up, because it affects what people believe about risk.

“Side effects mean it is not working.” Hot flashes and fatigue reflect falling hormone levels, which is precisely the intended effect. They say nothing, in either direction, about what the cancer is doing; PSA and follow-up do that.

“Supplements can replace or boost it.” No dietary supplement has been shown in mainstream evidence to treat breast or prostate cancer, and some interact with these medicines. Anything taken alongside should be on the plan.

“Prostate hormone therapy is the same as treatment for low testosterone.” It is the reverse. Testosterone replacement is generally avoided in men with active prostate cancer, which is a point to raise if another clinician ever suggests it.

Each misunderstanding can be turned into a question. Asking “Is this true in my case?” is faster, and kinder to yourself, than carrying an assumption for five years.

Questions to ask about hormone therapy: a checklist for your next appointment

Bring this list, cross off what the plan already answers, and ask for the rest in writing. The order follows the plan from top to bottom.

  • Rationale: What in my pathology or blood results shows this cancer is hormone sensitive? How strong is that signal?
  • Purpose: Is this treatment adjuvant, neoadjuvant or primary? What is it meant to achieve for me specifically, and how will we know?
  • Choice of class: Why this class rather than the alternatives? What about my menopausal status, other conditions or preferences shaped that choice?
  • Duration: What is the planned length, which evidence set it, and what would shorten or extend it?
  • Schedule: Continuous or intermittent? Daily tablet, periodic injection, or both? Who organizes repeats?
  • Monitoring: Which tests will be done, how often, and by whom? Bone density, PSA, testosterone, lipids, glucose, gynecologic review?
  • Side effects: Which ones are most likely for me, which are serious, and what is the first step for each?
  • Switching: If I cannot tolerate this medicine, what are the recognized alternatives, and after how long would you consider a change?
  • Interactions: Which medicines, supplements or foods should I avoid or report?
  • Fertility and intimacy: How does this affect fertility, contraception, sexual function and relationships, and what support is available?
  • Other clinicians: What should my primary care doctor, dentist or other specialists know?
  • Contact: Who do I call with a problem, including out of hours, and which symptoms justify an urgent call?
  • End of treatment: What happens when it finishes? How does follow-up change?
  • Decisions: What would make you recommend stopping, and what would you want to know from me before that decision?

Fourteen questions sound like a lot for a clinic slot. Most teams welcome them, and many can be answered by a specialist nurse or pharmacist outside the consultation. The aim is a plan you could explain to a friend, line by line, without looking anything up.

When to call your doctor

Most of what hormone therapy brings is a slow adjustment, but a short list of symptoms should prompt a same-day call to your oncology team or, where indicated, emergency care. These are drawn from the safety information published by the Mayo Clinic, the NHS and the National Cancer Institute for these drug classes.

For anyone on hormone therapy for breast cancer, seek urgent help for a swollen, painful or warm calf, sudden breathlessness, chest pain, coughing up blood, or sudden weakness, numbness, confusion or trouble speaking; these can signal a blood clot or stroke, risks associated with tamoxifen. Any vaginal bleeding after menopause, or new heavy or irregular bleeding before it, should be reported promptly so the uterine lining can be assessed. Vision changes, severe or persistent bone pain, or a fall with pain afterward also warrant a call, particularly on an aromatase inhibitor where bone density may be reduced.

For anyone on androgen deprivation therapy, call urgently for chest pain, pressure or tightness, sudden breathlessness, fainting, or a sudden irregular or racing heartbeat, given the cardiovascular associations with long-term ADT. New or worsening back pain with leg weakness, numbness, or loss of bladder or bowel control is an emergency, because it can indicate pressure on the spinal cord from the cancer rather than a side effect. Difficulty passing urine, bone pain that wakes you, or a fracture after minor trauma should be reported the same day. In the first weeks after a first GnRH agonist injection, a sharp increase in urinary or bone symptoms may reflect the testosterone flare and should be discussed without delay.

In both cancers, report a persistently low mood, thoughts of self-harm, severe or escalating fatigue, yellowing of the skin or eyes, or any symptom that is new and unexplained. Your plan should list the number to call and the hours it is staffed. When in doubt, the right move is to call; the treating team would rather hear about a false alarm than miss a real one.

Frequently asked questions

What are the most important questions to ask about hormone therapy at the first appointment?

Ask why your cancer is expected to respond, which drug class is proposed and why, how long treatment is planned, which side effects will be monitored and how, and what would prompt a change of plan. Request the answers in writing. These five questions cover the rationale, the mechanism, the timeline and the safety net, and they give you a framework for every later review.

How long does hormone therapy last for breast cancer?

For early hormone receptor positive breast cancer, adjuvant endocrine therapy is typically taken for 5 to 10 years according to the National Cancer Institute, with many plans built around a minimum of about five years. Whether a person continues to the longer end depends on tumor features, how the first years were tolerated and personal priorities. For cancer that has spread, treatment continues as long as it is controlling the disease.

What are the most common androgen deprivation therapy side effects?

Hot flashes, fatigue, reduced sex drive and difficulty with erections are among the most frequently reported, usually beginning within the first weeks to months as testosterone falls. Over longer periods, loss of muscle, weight gain around the waist, reduced bone density, changes in blood sugar and cholesterol, breast tenderness and mood changes can occur. Each has recognized management approaches, which is why monitoring is written into the plan.

Tamoxifen or aromatase inhibitor: how do oncologists choose?

The choice rests mainly on menopausal status and side-effect profile. Tamoxifen blocks the estrogen receptor and can be used before or after menopause, with uncommon but important risks of blood clots and uterine lining cancer. Aromatase inhibitors lower estrogen production, are used alone only after menopause, and commonly cause joint aches and bone thinning. Many plans use one then the other, and switching for intolerable side effects is a recognized option.

Does hormone therapy mean I am being given hormones?

No. In both breast and prostate cancer the treatment removes or blocks hormones rather than adding them. Breast cancer endocrine therapy blocks estrogen’s receptor or lowers estrogen levels; prostate cancer androgen deprivation lowers testosterone or blocks its receptor. The confusion with menopausal hormone replacement is common and worth raising with your team, because it affects how people understand the risks and purpose of treatment.

What are hormone therapy side effects that need an urgent call?

For breast cancer treatment: a swollen painful calf, sudden breathlessness, chest pain, stroke-like symptoms, or any vaginal bleeding after menopause. For androgen deprivation therapy: chest pain, fainting, a racing or irregular heartbeat, or back pain with leg weakness or loss of bladder or bowel control, which can signal spinal cord pressure. In either case, persistent low mood or thoughts of self-harm also warrant a same-day call.

Can I stop hormone therapy if I feel fine?

Feeling well is the expected state during hormone therapy, not a sign that it has finished its work, because the treatment acts on cells you cannot feel. The National Cancer Institute notes that stopping early reduces the benefit. Any decision to pause, switch or stop belongs with the treating team, who can weigh your side effects against the evidence on duration for your specific situation.

What is intermittent androgen deprivation therapy?

Intermittent therapy means treatment is paused once PSA falls to a set level and restarted if PSA rises again, rather than continuing without a break. The National Cancer Institute describes it as an approach studied to reduce side effects for some men with prostate cancer. Whether it is appropriate depends on the extent of disease and other factors, so it is a question for your oncologist rather than a default.

Why does my prostate cancer plan include a bone density scan?

Testosterone helps maintain bone, and androgen deprivation therapy lowers it to very low levels, so bone density declines over time and fracture risk rises. A baseline scan allows your team to track that change and act if needed. Weight-bearing exercise, resistance training, adequate calcium and vitamin D and not smoking are the evidence-based foundations that support bone health during treatment.

Can supplements or diet replace hormone therapy for breast or prostate cancer?

No dietary supplement has been shown in mainstream evidence to treat breast or prostate cancer, and some interact with the medicines used. A balanced diet, regular physical activity and maintaining a healthy weight support overall health during treatment and help counter some side effects, but they are not substitutes. Anything you take alongside your medicine should be listed on your plan and reviewed by your team.

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.

Dr. Şule Eren
Dr. Şule Eren, MD
Author
View profile →
Published November 22, 2026
Keep Reading

More from the Blog

We’re With You at Every Step

How can we help you today?

We value your privacy We use essential cookies to run this site and, with your consent, analytics cookies to understand how it is used and improve it. You can accept, reject, or choose what to allow. See our Cookie Policy.